Guardant Health (GH) Stock Forecast & Price Target

Compare

2,170 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GH Analyst Ratings

Strong Buy

21 Buy

0 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Guardant

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GH Stock 12 Month Forecast

Average Price Target

$112.47

▲(10.98% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $112.47 with a high forecast of $155.00 and a low forecast of $60.00. The average price target represents a 10.98% change from the last price of $101.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"$29","156":"$156","60.75":"$60.8","92.5":"$92.5","124.25":"$124.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$155.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$112.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,60.75,92.5,124.25,156],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,105.22,109.04923076923077,112.87846153846154,116.70769230769231,120.53692307692307,124.36615384615385,128.19538461538463,132.02461538461537,135.85384615384615,139.68307692307692,143.5123076923077,147.34153846153845,151.17076923076922,{"y":155,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,105.22,105.7776923076923,106.33538461538461,106.89307692307692,107.45076923076923,108.00846153846153,108.56615384615384,109.12384615384616,109.68153846153847,110.23923076923077,110.79692307692308,111.35461538461539,111.91230769230769,{"y":112.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,105.22,101.74153846153845,98.26307692307692,94.78461538461538,91.30615384615385,87.8276923076923,84.34923076923077,80.87076923076923,77.3923076923077,73.91384615384615,70.4353846153846,66.95692307692308,63.47846153846154,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.52,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.51,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.02,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.22,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$155.00

Average Price Target$112.47

Lowest Price Target$60.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kyle Mikson CFA

Canaccord Genuity

$100→$125

Buy

23.35%

Upside

Reiterated

12/22/25

Guardant Health price target raised to $125 from $100 at CanaccordGuardant Health price target raised to $125 from $100 at Canaccord

Tycho Peterson

Jefferies

$115→$130

Buy

28.28%

Upside

Reiterated

12/17/25

Jefferies Sticks to Its Buy Rating for Guardant Health (GH)

Bradley Bowers

Mizuho Securities

$100→$120

Buy

18.41%

Upside

Reiterated

12/17/25

Guardant Health price target raised to $120 from $100 at MizuhoGuardant Health price target raised to $120 from $100 at Mizuho

William Bonello

Craig-Hallum

Buy

―

Reiterated

12/16/25

Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Natera (NTRA)

Brandon Couillard

Wells Fargo

$93→$120

Buy

18.41%

Upside

Reiterated

12/15/25

Guardant Health price target raised to $120 from $93 at Wells FargoGuardant Health price target raised to $120 from $93 at Wells Fargo

Michael Ryskin

Bank of America Securities

$100→$120

Buy

18.41%

Upside

Reiterated

12/15/25

Bank of America Securities Sticks to Its Buy Rating for Guardant Health (GH)

Puneet Souda

Leerink Partners

$85→$155

Buy

52.95%

Upside

Reiterated

12/15/25

Guardant Health: Strong Growth Potential and Market Positioning Justify Buy Rating

Casey Woodring

J.P. Morgan

$90→$120

Buy

18.41%

Upside

Reiterated

12/15/25

Guardant Health price target raised to $120 from $90 at JPMorganGuardant Health price target raised to $120 from $90 at JPMorgan

Luke Sergott

Barclays

$85→$120

Buy

18.41%

Upside

Reiterated

12/15/25

Barclays Sticks to Their Buy Rating for Guardant Health (GH)

Patrick B Donnelly

Citi

$100→$135

Buy

33.21%

Upside

Reiterated

12/12/25

Guardant Health (GH) Gets a Buy from Citi

Mark Massaro

BTIG

$100→$140

Buy

38.15%

Upside

Reiterated

12/12/25

BTIG Keeps Their Buy Rating on Guardant Health (GH)

Kallum Titchmarsh

Morgan Stanley

$105→$130

Buy

28.28%

Upside

Reiterated

12/02/25

Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH) and Simulations Plus (NASDAQ: SLP)

David Westenberg

Piper Sandler

$90→$120

Buy

18.41%

Upside

Reiterated

11/10/25

Guardant Health price target raised to $120 from $90 at Piper SandlerGuardant Health price target raised to $120 from $90 at Piper Sandler

Daniel Arias

Stifel Nicolaus

$70→$100

Buy

-1.32%

Downside

Reiterated

11/03/25

Guardant Health price target raised to $100 from $70 at StifelGuardant Health price target raised to $100 from $70 at Stifel

Daniel Brennan

TD Cowen

$72→$100

Buy

-1.32%

Downside

Reiterated

10/30/25

Guardant Health: Strong Performance and Growth Potential Drive Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kyle Mikson CFA

Canaccord Genuity

$100→$125

Buy

23.35%

Upside

Reiterated

12/22/25

Guardant Health price target raised to $125 from $100 at CanaccordGuardant Health price target raised to $125 from $100 at Canaccord

Tycho Peterson

Jefferies

$115→$130

Buy

28.28%

Upside

Reiterated

12/17/25

Jefferies Sticks to Its Buy Rating for Guardant Health (GH)

Bradley Bowers

Mizuho Securities

$100→$120

Buy

18.41%

Upside

Reiterated

12/17/25

Guardant Health price target raised to $120 from $100 at MizuhoGuardant Health price target raised to $120 from $100 at Mizuho

William Bonello

Craig-Hallum

Buy

―

Reiterated

12/16/25

Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Natera (NTRA)

Brandon Couillard

Wells Fargo

$93→$120

Buy

18.41%

Upside

Reiterated

12/15/25

Guardant Health price target raised to $120 from $93 at Wells FargoGuardant Health price target raised to $120 from $93 at Wells Fargo

Michael Ryskin

Bank of America Securities

$100→$120

Buy

18.41%

Upside

Reiterated

12/15/25

Bank of America Securities Sticks to Its Buy Rating for Guardant Health (GH)

Puneet Souda

Leerink Partners

$85→$155

Buy

52.95%

Upside

Reiterated

12/15/25

Guardant Health: Strong Growth Potential and Market Positioning Justify Buy Rating

Casey Woodring

J.P. Morgan

$90→$120

Buy

18.41%

Upside

Reiterated

12/15/25

Guardant Health price target raised to $120 from $90 at JPMorganGuardant Health price target raised to $120 from $90 at JPMorgan

Luke Sergott

Barclays

$85→$120

Buy

18.41%

Upside

Reiterated

12/15/25

Barclays Sticks to Their Buy Rating for Guardant Health (GH)

Patrick B Donnelly

Citi

$100→$135

Buy

33.21%

Upside

Reiterated

12/12/25

Guardant Health (GH) Gets a Buy from Citi

Mark Massaro

BTIG

$100→$140

Buy

38.15%

Upside

Reiterated

12/12/25

BTIG Keeps Their Buy Rating on Guardant Health (GH)

Kallum Titchmarsh

Morgan Stanley

$105→$130

Buy

28.28%

Upside

Reiterated

12/02/25

Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH) and Simulations Plus (NASDAQ: SLP)

David Westenberg

Piper Sandler

$90→$120

Buy

18.41%

Upside

Reiterated

11/10/25

Guardant Health price target raised to $120 from $90 at Piper SandlerGuardant Health price target raised to $120 from $90 at Piper Sandler

Daniel Arias

Stifel Nicolaus

$70→$100

Buy

-1.32%

Downside

Reiterated

11/03/25

Guardant Health price target raised to $100 from $70 at StifelGuardant Health price target raised to $100 from $70 at Stifel

Daniel Brennan

TD Cowen

$72→$100

Buy

-1.32%

Downside

Reiterated

10/30/25

Guardant Health: Strong Performance and Growth Potential Drive Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Guardant Health

1 Month

xxx

Success Rate

8/12 ratings generated profit

Average Return

+6.47%

reiterated a xxx

rating 10 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +6.47% per trade.

3 Months

xxx

Success Rate

9/13 ratings generated profit

Average Return

+41.30%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +41.30% per trade.

1 Year

Daniel BrennanTD Cowen

Success Rate

13/14 ratings generated profit

Average Return

+92.71%

reiterated a buy rating 2 months ago

Copying Daniel Brennan's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +92.71% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+170.43%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +170.43% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GH Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GH has received 34 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. GH average Analyst price target in the past 3 months is 112.47.

Each month's total comprises the sum of three months' worth of ratings.

GH Financial Forecast

GH Earnings Forecast

Next quarter’s earnings estimate for GH is -$0.78 with a range of -$0.87 to -$0.69. The previous quarter’s EPS was -$0.74. GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.

GH Sales Forecast

Next quarter’s sales forecast for GH is $267.82M with a range of $264.60M to $270.01M. The previous quarter’s sales results were $265.20M. GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.

GH Stock Forecast FAQ

What is GH’s average 12-month price target, according to analysts?

Based on analyst ratings, Guardant Health’s 12-month average price target is 112.47.

What is GH’s upside potential, based on the analysts’ average price target?

Guardant Health has 10.98% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GH a Buy, Sell or Hold?

Guardant Health has a consensus rating of Strong Buy which is based on 21 buy ratings, 0 hold ratings and 0 sell ratings.

What is Guardant Health’s price target?

The average price target for Guardant Health is 112.47. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $155.00 ,the lowest forecast is $60.00. The average price target represents 10.98% Increase from the current price of $101.34.

What do analysts say about Guardant Health?

Guardant Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of GH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Guardant Health (GH) Stock Forecast & Price Target

GH Analyst Ratings

GH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Guardant Health

GH Analyst Recommendation Trends

GH Financial Forecast

GH Earnings Forecast

GH Sales Forecast

GH Stock Forecast FAQ

Detailed List of Analyst Forecasts